, Volume 78, Issue 13, pp 1289–1296 | Cite as

Fenofibrate and Dyslipidemia: Still a Place in Therapy?

  • Nicola Tarantino
  • Francesco Santoro
  • Michele Correale
  • Luisa De Gennaro
  • Silvio Romano
  • Matteo Di Biase
  • Natale Daniele BrunettiEmail author
Current Opinion


Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment—which represents the cornerstone of therapy—a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field.


Compliance with Ethical Standards


No external funding was used in the preparation of this manuscript.

Conflict of interest

Nicola Tarantino, Francesco Santoro, Michele Correale, Luisa De Gennaro, Silvia Romano, Matteo Di Biase and Natale Daniele Brunetti declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.


  1. 1.
    Global Burden of Disease Study. Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2013;2015(386):743–800.Google Scholar
  2. 2.
    Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Comparative Risk Assessment Collaborating Group. Lancet. 2002;360:1347–60.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2005;1:217–25.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Hossain P, Kawar B, El NM. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356:213–5.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195–211.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. EurHeart J. 2016;37:2999–3058.Google Scholar
  8. 8.
    Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia And Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl 2):1–87.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011;6(Suppl 1):45–51.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Halcox J, Misra A. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat? Metab Syndr Relat Disord. 2015;13:1–21.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag. 2017;13:29–41.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Okopień B, Buldak L, Bołdys A. Fibrates in the management of atherogenic dyslipidemia. Expert Rev Cardiovasc Ther. 2017;15:913–21.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, Farnier M, Ferrières J, Filardi PP9, Hancu N, Kayikcioglu M, Mello E Silva A, Millan J, Reiner Ž, Tokgozoglu L, Valensi P17, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Catapano AL. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(Suppl C):C2–C12.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Cannon CP. Combination therapy in mixed dyslipidemia. J Intern Med. 2008;263:35365.CrossRefGoogle Scholar
  15. 15.
    Goldberg IJ. Fat in the blood, fat in the artery, fat in the heart: triglyceride in physiology and disease. Arterioscler Thromb Vasc Biol. 2018;38:700–6.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K, Saito K, Maekawa M, Kanno T. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem. 2001;47:893–900.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ginsberg Henry N, MacCallum Paul R. The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4:113–9.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Cecilia C, Wang L, Hess CN, Hiatt WR, Goldfine AB. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes—mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–502.CrossRefGoogle Scholar
  19. 19.
    Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A. Fibrate therapy: an update. Cardiol Rev. 2008;16:129–41.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C–18C.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Teramoto T, Abe K, Taneyama T. Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Cardiovasc Diabetol. 2013;12:163.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. J Lipid Res. 2017;58:2180–2187.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83(5B):9–20.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200–5.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001;357(9260):905–10.CrossRefGoogle Scholar
  26. 26.
    Tsunoda F, Asztalos IB, Horvath KV, Steiner G, Schaefer EJ, Asztalos BF. Fenofibrate, HDL, and Cardiovascular Disease in Type-2 Diabetes: the DAIS Trial. Atherosclerosis. 2016;247:35–9.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C. Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Kawasaki R, Konta T, Nishida K. Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database. Diabetes Obes Metab. 2018. Scholar
  29. 29.
    Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C. Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–8.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Ginsberg HN, Elam MB, Lovato LC, et al. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    The ACCORD Study Group and ACCORD Eye Study. Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.CrossRefGoogle Scholar
  32. 32.
    Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22:55–61.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–8.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396–401.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol. 2008;101:486–9.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157:195–203.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig. 2004;24:465–77.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Ghani RA, Bin Yaakob I, Wahab NA, Zainudin S, Mustafa N, Sukor N, Wan Mohamud WN, Kadir KA, Kamaruddin NA. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. J Clin Lipidol. 2013;7:446–53.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Harmer JA, Keech AC, Veillard AS, Skilton MR, Marwick TH, Watts GF, Meredith IT, Celermajer DS, FIELD Vascular Study Investigators. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: a FIELD substudy. Atherosclerosis. 2015;242:295–302.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Koh KK, Quon MJ, Lim S, Lee Y, Sakuma I, Lee YH, Han SH, Shin EK. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis. 2011;214:144–7.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010;95:829–36.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Krysiak R, Gdula-Dymek A, Okopien B. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances. Basic Clin Pharmacol Toxicol. 2013;112:198–202.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O’Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370–380.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Oikawa S, Yamashita S, Nakaya N, Sasaki J. Kono S; Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: results of the EFECTL Study. J Atheroscler Thromb. 2017;24:77–94.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Pettersen JC, Pruimboom-Brees I, Francone OL, Amacher DE, Boldt SE, Kerlin RL, Ballinger WE. The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. Toxicol Pathol. 2012;40:435–47.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990;40:260–90.CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H, Shimoi K. Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. J Toxicol Sci. 2009;34:377–87.CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110:1296–301.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Food and Drug Administration. FDA drug safety communication: review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial. 2011.Google Scholar
  50. 50.
    Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C–81C.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015;10:CD009580.
  52. 52.
    Hodson R. Precision medicine. Nature. 2016;537(7619):S49.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Irvin MR, Zhang Q, Kabagambe EK, Perry RT, Straka RJ, Tiwari HK, Borecki IB, Shimmin LC, Stuart C, Zhong Y, Hixson JE, Arnett DK. Rare PPARA variants and extreme response to fenofibrate in the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genom. 2012;22:367–72.Google Scholar
  54. 54.
    Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SL. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet. 2008;16:603–13.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN9, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner M, Motsinger-Reif AA; ACCORD/ACCORDion Investigators. Genetic variants in HSD17B3, SMAD3, and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes. Clin Pharmacol Ther. 2018;103:712–721.Google Scholar
  56. 56.
    Morieri ML, Shah H, Doria A, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Genetic Study Group. Variants in ANGPTL4 and the risk of coronary artery disease. N Engl J Med. 2016;375:2304–5.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25:521–38.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR agonists and metabolic syndrome: an established role? Int J Mol Sci. 2018;19(4):1197.CrossRefPubMedCentralGoogle Scholar
  59. 59.
    Anon. Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT). Accessed 18 June 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Nicola Tarantino
    • 1
  • Francesco Santoro
    • 1
    • 2
  • Michele Correale
    • 3
  • Luisa De Gennaro
    • 4
  • Silvio Romano
    • 5
  • Matteo Di Biase
    • 6
  • Natale Daniele Brunetti
    • 1
    Email author
  1. 1.Department of Medical and Surgical SciencesUniversity of FoggiaFoggiaItaly
  2. 2.Asklepios Klinik Sankt GeorgHamburgGermany
  3. 3.Cardiology DepartmentOspedali Riuniti University HospitalFoggiaItaly
  4. 4.Ospedale San PaoloBariItaly
  5. 5.University of L’AquilaL’AquilaItaly
  6. 6.Clinica Santa MariaGruppo Villa Maria Care and ResearchBariItaly

Personalised recommendations